Volume 63, Issue 1, Pages (January 2013)

Slides:

Advertisements

Similar presentations

European Urology Focus

Advertisements

Volume 57, Issue 3, Pages (March 2010)

Volume 187, Issue 6, Pages (June 2012)

Impact of LUTS Using Bother Index in DAN-PSS-1 Questionnaire

Volume 55, Issue 1, Pages 1-8 (January 2009)

Volume 180, Issue 3, Pages (September 2008)

Volume 70, Issue 3, Pages (September 2016)

Volume 59, Issue 2, Pages (February 2011)

Volume 45, Issue 5, Pages (May 2004)

The PSA Era is not Over for Prostate Cancer

Volume 54, Issue 2, Pages (August 2008)

Volume 68, Issue 6, Pages (December 2015)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 61, Issue 6, Pages (June 2012)

Volume 66, Issue 4, Pages (October 2014)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 1, Pages (January 2016)

Volume 71, Issue 5, Pages (May 2017)

Volume 52, Issue 3, Pages (September 2007)

Prostate Cancer Epidemic in Sight?

Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer Olav Erich Yri, Trine Bjoro, Sophie D.

Volume 72, Issue 5, Pages (November 2017)

Volume 62, Issue 6, Pages (December 2012)

Volume 59, Issue 2, Pages (February 2011)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Volume 59, Issue 4, Pages (April 2011)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 54, Issue 2, Pages (August 2008)

Prostate Cancer Detection: A View of the Future

Laurent Boccon-Gibod European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Yuanshan Cui, Yong Zhang European Urology

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Leonard S. Marks, Jiaoti Huang European Urology

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 66, Issue 2, Pages (August 2014)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 50, Issue 3, Pages (September 2006)

Volume 50, Issue 5, Pages (November 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 51, Issue 1, Pages (January 2007)

Volume 55, Issue 6, Pages (June 2009)

Testicular Cancer Variations in Time and Space in Europe

Volume 53, Issue 1, Pages (January 2008)

Volume 72, Issue 2, Pages (August 2017)

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 53, Issue 6, Pages (June 2008)

Christian Stief European Urology Supplements

European Urology is “Your” Journal

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 65, Issue 6, Pages (June 2014)

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.

Improving Flexibility and Quality of Life for Your Patients: A Must?

Economic Burden of Bladder Cancer Across the European Union

Volume 53, Issue 6, Pages (June 2008)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 54, Issue 3, Pages (September 2008)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 51, Issue 5, Pages (May 2007)

Volume 69, Issue 4, Pages (April 2016)

Presentation transcript:

Volume 63, Issue 1, Pages 111-120 (January 2013) Advanced Prostate Cancer Treated with Intermittent or Continuous Androgen Deprivation in the Randomised FinnProstate Study VII: Quality of Life and Adverse Effects Arto J. Salonen, Kimmo Taari, Martti Ala-Opas, Jouko Viitanen, Seppo Lundstedt, Teuvo L.J. Tammela European Urology Volume 63, Issue 1, Pages 111-120 (January 2013) DOI: 10.1016/j.eururo.2012.07.040 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Differences in quality of life between treatment arms according to (a–d) Mann-Whitney U test (*p<0.05) and (e–h) the 0.5 standard deviation rule in the domains of activity limitation, physical capacity, sexual functioning, and sexuality. Lower scores indicate better health in activity limitation, physical capacity, and sexuality; higher scores indicate better sexual functioning. SD=standard deviation; TOFF=treatment-off phase; TON=treatment-on phase. European Urology 2013 63, 111-120DOI: (10.1016/j.eururo.2012.07.040) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Differences in quality of life between treatment arms in the domains of activity limitation (n=48 [IAD] vs 44 [CAD]; p=0.06], physical capacity (n=48 vs 44; p=0.07), and sexual functioning (n=46 vs 41; p=0.003) analyzed by repeated measures analysis of variance with covariant of visit 3 (randomisation). Lower scores indicate better health in activity limitation and physical capacity; higher scores indicate better sexual functioning. CAD=continuous androgen deprivation treatment arm; IAD=intermittent androgen deprivation treatment arm; TOFF=treatment-off phase; TON=treatment-on phase. European Urology 2013 63, 111-120DOI: (10.1016/j.eururo.2012.07.040) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Proportion of respondents in domain 9 (sexual functioning) who continued to domain 10 (sexuality) in intermittent androgen deprivation (IAD) and continuous androgen deprivation (CAD) treatment arms. European Urology 2013 63, 111-120DOI: (10.1016/j.eururo.2012.07.040) Copyright © 2012 European Association of Urology Terms and Conditions